Valgen Medtech
Valgen Medtech is a Chinese medical device company developing transcatheter edge-to-edge repair (TEER) systems for mitral and tricuspid valve disease. Its flagship DragonFly holds #1 China TEER market share, with 2,000+ procedures performed across 15+ countries.
- Company typePrivate
- Founded2015
- HeadquartersHangzhou, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Valgen Medtech does
Valgen Medtech (杭州德晋医疗科技有限公司) is a Hangzhou, China-based medical device company founded in 2015 that develops interventional products for structural heart disease, with primary focus on transcatheter edge-to-edge repair (TEER) systems for mitral and tricuspid regurgitation. The company's flagship product is the DragonFly transcatheter mitral valve clip system, supported by a portfolio of complementary devices and accessories including the MitralStitch transapical mitral repair system, the DragonFly-T transcatheter tricuspid repair system, the DragonFire transcatheter RF ablation system for HOCM, and procedure-enabling accessories such as the Magpie balloon dilation catheter, DragonPath transseptal puncture system, Firework stiff guidewire, Pu Jie Jie X-ray protective screen, and an Adjustable Curved Introducer Sheath. Valgen serves cardiac surgery centers and interventional cardiology hospitals, with DragonFly implants performed in approximately 300 hospitals in China and the company holding regulatory approvals in 15+ countries.
The business model is B2B sale of high-value, single-use interventional devices on a per-procedure basis, with revenue generated by hospital procurement of the clip system and required accessories. Commercial reach is reinforced by the Long Fei Academy physician training program, which conducts more than 100 training events per year and serves as both a clinical adoption engine and a switching-cost moat. In 2025 Valgen performed 2,043 DragonFly implants in China and captured 47.14% of the China TEER market, the leading domestic position. Clinical evidence supporting commercial traction includes 87.5% one-year and 82.5% three-year DMR composite success rates in China, 86.7% one-year DMR and 97.4% procedural success in the EU, and 96.2% device success for DragonFly-T. The company is a privately-held subsidiary of Deno Healthcare Group, backed by DCP and Sequoia China following a $188M Series B in 2021, and was recognized as a Unicorn Enterprise.
Recent strategic priorities include expanding the DragonFly indication scope (DMR and FMR approvals in the EU), launching the DragonFire HOCM ablation line, developing the next-generation DragonFly M2 platform, and executing a sequenced international rollout into the EU, Latin America, the Middle East, and Southeast Asia. The company has 250+ employees, 600+ patents filed with 200+ granted, overseas R&D and clinical training centers, and a leadership team led by CEO Yiwei Zhao and General Manager Dr. Zhang Tingchao. A 2026 headquarters relocation is planned to support continued scale-up.
Valgen Medtech firmographics
Firmographics- Name
- Valgen Medtech
- Legal name
- 杭州德晋医疗科技有限公司
- Website
- https://valgenmed.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Valgen Medtech is a Chinese medical device company developing transcatheter edge-to-edge repair (TEER) systems for mitral and tricuspid valve disease. Its flagship DragonFly holds #1 China TEER market share, with 2,000+ procedures performed across 15+ countries.
- Ownership category
- akta.pro rank
Valgen Medtech industry classification
Industry- Product category
- Interventional Cardiology Devices — Structural Heart (Transcatheter Mitral and Tricuspid Valve Repair)
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro industry
- Structural Heart Valves (TAVR/SAVR) & Valve RepairHealthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
Keywords
Where Valgen Medtech is headquartered
LocationHeadquarters
- HQ city
- Hangzhou
- HQ country
- China
- HQ region
- Asia
Offices5 records
Markets served
Valgen Medtech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Others
Revenue model
- Medical device sales (capital equipment & consumables): Primary revenue from one-time/transaction-based sales of Class III medical devices (DragonFly™ mitral clip system, Magpie™ balloon dilation catheter, DragonPath™ transseptal puncture system, Pu Jie Jie™ X-ray shield, Stiff guidewires) to hospitals and clinical centers; 2,000+ DragonFly™ surgeries across ~300 hospitals in China by end of 2025.
- International device sales & overseas commercialization: Revenue from DragonFly™ and other device sales in approved international markets including Hong Kong, Indonesia, Colombia, Turkey, Peru, Brazil, Saudi Arabia, Jordan, Panama, Philippines, Vietnam, Argentina, and EU; commercial adoption underway in Latin America and Southeast Asia.
Go-to-market motion4 records
Distribution channels5 records
Marketing channels9 records
Valgen Medtech product offering
Product offeringCore offering
Valgen Medtech develops, manufactures, and commercializes Class III transcatheter interventional medical devices for structural heart disease, primarily mitral and tricuspid valve regurgitation. Its flagship DragonFly™ transcatheter mitral valve clip system performs transfemoral-transseptal edge-to-edge repair (TEER) and is sold alongside a procedural toolkit of supporting devices (MitralStitch®, DragonFly-T®, DragonFire®, DragonPath™, Magpie™, Pu Jie Jie™, stiff guidewires, and an adjustable curved introducer sheath) used by interventional cardiologists in hospitals.
Product overview
Valgen Medtech operates as a single unified structural heart disease interventional medical device company with a platform-plus-modules product architecture centered on the DragonFly™ product family for transcatheter mitral and tricuspid valve repair. The core product DragonFly™ Transcatheter Mitral Valve Clip System (transfemoral venous approach) is supported by a comprehensive procedural toolkit including the MitralStitch® (transapical mitral valve repair), DragonFly-T® (transcatheter tricuspid valve repair, in clinical research), and DragonFire® (transcatheter radiofrequency ablation for hypertrophic cardiomyopathy, in innovation channel). The system is complemented by accessory/supporting products that together form a complete procedural solution: DragonPath™ (atrial septal puncture system), Magpie™ (balloon dilation catheter), Firework™ stiff guidewire series, Pu Jie Jie™ (medical X-ray protective screen), and the newly approved Adjustable Curved Introducer Sheath. This integrated portfolio enables both mitral and tricuspid valve transcatheter edge-to-edge repair (TEER) procedures through transfemoral venous and transapical approaches, with the DragonFly™ serving as the flagship product that achieved #1 market share in China's TEER market in 2025 with 47.14% of total Chinese TEER implant volume.
Differentiator
Problem solved
Functional benefit
Brands
- DragonFly™: Transcatheter mitral valve clip system (and the DragonFly-T variant for tricuspid repair); the company's flagship product line, including next-generation DragonFly M2 steerable introducer sheath.
- Pu Jie Jie™ (蒲姐姐)
- Magpie™
- DragonPath™
- Firework™ (硬导丝 stiff guidewire series)
- DragonFire®
- MitralStitch®
Products and services
- DragonFly™ Transcatheter Mitral Valve Clip System Transfemoral venous transcatheter mitral valve edge-to-edge repair (TEER) system for treating degenerative mitral regurgitation (DMR) and functional mitral regurgitation (FMR) in high-surgical-risk adult patients. Features 4 clip specifications, 45° adjustable closure angle, independent leaflet capture, central occluder mesh, and visualized quantitative operating system. Sold to interventional cardiologists at tertiary hospitals and cardiac centers.
- DragonFly-T® Transcatheter Tricuspid Valve Edge-to-Edge Repair System Transcatheter tricuspid valve edge-to-edge repair (T-TEER) system designed specifically for tricuspid valve anatomy. FIM feasibility study showed 96.2% device success rate and 89.8% of patients achieving ≥1-grade TR reduction at 12 months. Sold / studied at tertiary cardiology centers performing tricuspid interventions.
- MitralStitch® Transapical Mitral Valve Repair System Transapical beating-heart mitral valve repair system capable of both artificial chordae implantation and edge-to-edge repair. Uses unique atrial-side pad and U-shaped suture design that reduces leaflet tension and preserves physiologic repair. Sold to interventional cardiology centers performing transapical mitral repair.
- DragonFire® Transcatheter Myocardial Radiofrequency Ablation System Transcatheter myocardial radiofrequency ablation system for treating hypertrophic obstructive cardiomyopathy (HOCM) patients. Minimally invasive, precise, and safe approach addressing a previously underserved Chinese HOCM treatment market. Targeted at interventional cardiologists and HCM programs.
- Magpie™ Balloon Dilation Catheter Non-compliant balloon dilation catheter suitable for dilation of the native aortic valve of the heart (not for post-dilation after prosthetic valve implantation). Features high rated burst pressure, rapid inflation/deflation, eight-petal folding wing design, and reinforced inner tube. Supporting product for Valgen's structural heart procedures.
- DragonPath™ Atrial Septal Puncture System Transseptal puncture system with optimized puncture sheath hardness, kink resistance, and torque performance; needle designed for stronger puncture force with appropriate tip angle. Used to establish transfemoral-transseptal access for the DragonFly™ TEER procedure.
- Pu Jie Jie™ Medical X-ray Protective Screen Medical X-ray radiation protective screen used for radiation protection during diagnostic radiology procedures. Features include a unique operation window, ultrasound probe hook, arm support bracket, suspension bracket, and cable management box. Supporting consumable product for interventional procedures.
- Firework™ Stiff Guidewire Series Stiff guidewire series for cardiovascular (non-coronary) interventional diagnosis and treatment procedures, used to guide device insertion and positioning or to establish vascular access.
- Adjustable Curved Introducer Sheath (可调弯导引鞘) NMPA-approved adjustable curved introducer sheath that overcomes large-sheath mid-sheath locking limitations, enabling improved Aorta Hugger performance in challenging transseptal cases. Supporting accessory for the DragonFly™ TEER procedure.
Quantifiable outcome
- 87.5% 1-year composite treatment success in DragonFly-DMR Chinese pivotal trial (n=120)
- +8 more outcomes
Companies that use Valgen Medtech
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
Valgen Medtech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature10 records
Valgen Medtech partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered flagship, core and minor.
- Second Affiliated Hospital of Zhejiang University, School of Medicine (浙大二院) - Prof. Wang Jian'an teamflagshipCo-developed DragonFly™ with Prof. Wang Jian'an's team at the Second Affiliated Hospital of Zhejiang University (now Academician Wang Jian'an's team). The first clinical use of DragonFly™ was performed by this team on July 23, 2020. They are the principal investigators for the DragonFly-DMR China pivotal trial, DragonFly-DMR EU Pivotal Study (at University Hospital Bonn), and DragonFly-T® FIM study. They broadcasted the first T-TEER case using DragonFly™ at CSI Frankfurt 2026.
- Sichuan University National Biomaterials Engineering Research Center - Prof. Zhang Xingdong team (四川大学国家生物材料工程研究中心)flagshipCo-developed DragonFly™ with Prof. Zhang Xingdong (Academician) and his team at the Sichuan University National Biomaterials Engineering Research Center. Co-led nearly a decade of R&D and jointly commercialized the device globally.
- Denuo Medical Group (德诺医疗集团 / 德诺医疗)flagshipValgen Medtech is a subsidiary / portfolio company of Denuo Medical Group, with Mr. Zi Zhenjun (訾振军) as Denuo's founding investor. Valgen operates the DragonFly™, MitralStitch®, DragonFire®, and other structural heart product lines under Denuo's umbrella; participates in Denuo's broader "Belt and Road" structural heart disease medical cooperation program with the National Center for Cardiovascular Disease.
- Qiming Medical / Venus Medtech (启明医疗)flagshipExclusive strategic marketing cooperation agreement with Qiming Medical (Venus Medtech) to accelerate promotion of cardiac valve disease diagnosis and treatment technology in China. Drives the bulk of Valgen's domestic channel sales and clinical adoption.
- University Hospital Bonn (Universitätsklinikums Bonn) - Prof. Georg NickenigflagshipLead European clinical research partner for DragonFly-EU Pivotal Study (8 European centers, 39 patients). Prof. Nickenig serves as principal investigator, presenting 1-year EU data at CSI Frankfurt 2026 and DragonFly-FMR 12-month data at EuroPCR 2025. Bonn Heart Center is a key global KOL partner.
- Xiamen University Affiliated Cardiovascular Hospital (厦心) - Prof. Wang Yan teamcoreKey clinical partner for "Belt and Road" international medical cooperation; treated an El Salvador medical expert with DragonFly™ in November 2025; conducts physician training and case demonstrations. Signed cooperation agreement with Rosales National Hospital in El Salvador (April 2025) and is a key node in Valgen's international clinical strategy.
- ASV Yaşam Hospital, Antalya, Turkey - Prof. Ismail AteşcoreTurkish clinical partner presenting real-world evidence on 5 high-risk cases of complex mitral/tricuspid regurgitation at CSI Frankfurt 2026; serves as a key KOL reference for the Turkish and broader European market.
- Fuwai Hospital, Chinese Academy of Medical Sciences - Prof. Pan Xiangbin team (中国医学科学院阜外医院)coreKey clinical partner in the development and clinical research of MitralStitch® — performed the first China-original DMR interventional case in 2018 and led the first-in-human clinical applications; supports "Belt and Road" medical cooperation programs.
- Brazilian clinical center (local interventional cardiology hospital in São Paulo)minorBrazilian clinical center that performed the first Latin American commercial implant of DragonFly™ on April 30, 2026, validating device performance in complex AFMR cases.
- Hanoi Medical University Hospital (Vietnam)minorPerformed the first Vietnam commercial implant of DragonFly™ on April 22, 2026 — a key clinical site for the Belt and Road Southeast Asia market entry.
Scale indicators17 records
Recent moves8 records
Expansion highlights6 records
Valgen Medtech competitors and assessment
Company assessmentBroad incumbents
- MicroPort Scientific: Large Chinese medical device conglomerate with structural heart and other interventional portfolios. A broad incumbent with overlapping capabilities in structural heart and a wide distribution network across Chinese hospitals.
- Edwards Lifesciences: Developer of the PASCAL transcatheter valve repair system, the second major global TEER platform competing directly with DragonFly™ and MitraClip. Edwards is a broad structural heart incumbent with established reimbursement and KOL penetration in EU and US markets.
- Abbott: Global market leader in transcatheter mitral repair via the MitraClip system (now multi-generation G4). Directly competes with Valgen's DragonFly™ in both China and international markets, with the deepest global KOL network, longest follow-up data, and broadest reimbursement footprint.
Direct peers
- Peijia Medical: Chinese structural heart company with a mitral and tricuspid valve interventional device portfolio. A direct domestic competitor to Valgen in the Chinese TEER and broader structural heart space, also pursuing international regulatory approvals.
- Venus Medtech (Qiming Medical): Chinese structural heart company developing VenusP-Valve and other transcatheter valve products. Both a strategic investor in Valgen (participated in Series B) and exclusive domestic channel partner (Qiming Medical) for DragonFly™, as well as a peer in the broader Chinese structural heart interventional space.
- Jenscare Scientific: Chinese medical device company developing the JensClip transcatheter mitral valve repair system, a direct domestic competitor to Valgen's DragonFly™ in the China TEER market. Competes for the same hospital accounts, surgeon training programs, and provincial reimbursement slots.
Emerging players
- InnovHeart: Italy-based developer of the Saturn transcatheter mitral valve replacement system. An emerging player in the mitral regurgitation interventional space, focused on TMVR rather than TEER, addressing a related but distinct patient segment.
- Cardiac Dimensions: Developer of the Carillon Mitral Contour System for functional mitral regurgitation. An emerging transcatheter alternative in the FMR space, addressing a subset of the same patient population that DragonFly™ is approved for (DragonFly received EU FMR approval in May 2026).
- 4C Medical Technologies: US-based company developing the AltaValve transcatheter mitral valve replacement system. A partial competitor in the mitral regurgitation treatment space; overlaps in target patient population (high-risk MR) but with a different mechanism (TMVR vs TEER).
Regional players
- NewMed Medical: Chinese structural heart company developing transcatheter valve products. A regional peer competing in the Chinese structural heart interventional market with overlapping target indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Valgen Medtech social profiles
Digital presenceValgen Medtech compliance and trust
Trust signalCompliance10 records
Valgen Medtech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Valgen Medtech leadership team
Management profileNumber of profiles
Profiles2 records
Valgen Medtech funding detail
Funding detailFunding overview
Funding rounds6 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Valgen Medtech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Valgen Medtech
What does Valgen Medtech do?
Valgen Medtech develops, manufactures, and commercializes Class III transcatheter interventional medical devices for structural heart disease, primarily mitral and tricuspid valve regurgitation. Its flagship DragonFly™ transcatheter mitral valve clip system performs transfemoral-transseptal edge-to-edge repair (TEER) and is sold alongside a procedural toolkit of supporting devices (MitralStitch®, DragonFly-T®, DragonFire®, DragonPath™, Magpie™, Pu Jie Jie™, stiff guidewires, and an adjustable curved introducer sheath) used by interventional cardiologists in hospitals.
Is Valgen Medtech a public or private company?
Valgen Medtech is a private company. It is classified as corporate owned and is currently operating.
When was Valgen Medtech founded?
Valgen Medtech was founded in 2015. It employs 11 to 50 people.
Where is Valgen Medtech based?
Valgen Medtech is headquartered in Hangzhou, China, in the Asia region.
How does Valgen Medtech make money?
Two revenue lines are on record. Medical device sales (capital equipment & consumables) is the primary driver. The others are international device sales & overseas commercialization.
Who are Valgen Medtech's main competitors?
Broad incumbents on record are MicroPort Scientific, Edwards Lifesciences and Abbott. Direct peers are Peijia Medical, Venus Medtech (Qiming Medical) and Jenscare Scientific. Emerging players are InnovHeart, Cardiac Dimensions and 4C Medical Technologies. NewMed Medical is listed as a regional player.
Does Valgen Medtech have an API?
No public API is recorded for Valgen Medtech.
What industry is Valgen Medtech in?
Valgen Medtech's product category is Interventional Cardiology Devices — Structural Heart (Transcatheter Mitral and Tricuspid Valve Repair). Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3842.